

# Phase I trial; HMR code: 24-003

<b>Submission date</b> 05/08/2024	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 12/08/2024	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 06/01/2025	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

## Contact information

### Type(s)

Principal investigator

### Contact name

Dr Adeep Puri

### Contact details

Hammersmith Medicines Research Limited  
Cumberland Avenue  
Park Royal  
London  
United Kingdom  
NW10 7EW  
+44 20 8961 4130  
rec@hmrlondon.com

### Type(s)

Public, Scientific

### Contact name

Dr Jeff Kent

### Contact details

455 E. Eisenhower Parkway  
Suite 300 PMB 1048  
Ann Arbor  
United States of America

MI 48108  
+1 734 887 9192  
info@slingtx.com

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Integrated Research Application System (IRAS)

1010220

### ClinicalTrials.gov (NCT)

Nil known

### Protocol serial number

IRAS 1010220; HMR code: 24-003; Sponsor code: SLG-TED-101

## Study information

### Scientific Title

Phase I trial; HMR code: 24-003 [The full scientific title will be published within 30 months after the end of the trial]

### Study objectives

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### Ethics approval required

Ethics approval required

### Ethics approval(s)

approved 30/07/2024, London – Surrey Borders Research Ethics Committee (Equinox House, City Link, Nottingham, NG2 4LA, United Kingdom; +44 207 104 8057; surreyboundaries.rec@hra.nhs.uk), ref: 24/LO/0492

### Study design

Pharmacokinetic and bioavailability study in up to 20 healthy volunteers

### Primary study design

Interventional

### Study type(s)

Other

### Health condition(s) or problem(s) studied

Healthy volunteers

### Interventions

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Intervention Type**

Drug

### **Phase**

Phase I

### **Drug/device/biological/vaccine name(s)**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Primary outcome(s)**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Key secondary outcome(s)**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

### **Completion date**

08/08/2025

## **Eligibility**

### **Key inclusion criteria**

Healthy volunteer

### **Participant type(s)**

Healthy volunteer

### **Healthy volunteers allowed**

No

### **Age group**

Adult

### **Sex**

All

### **Key exclusion criteria**

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

**Date of first enrolment**

14/08/2024

**Date of final enrolment**

08/05/2025

## Locations

**Countries of recruitment**

United Kingdom

England

**Study participating centre**

**Hammersmith Medicines Research Limited**

Cumberland Avenue

London

United Kingdom

NW10 7EW

## Sponsor information

**Organisation**

Sling Therapeutics, Inc.

## Funder(s)

**Funder type**

Industry

**Funder Name**

Sling Therapeutics, Inc.

## Results and Publications

**Individual participant data (IPD) sharing plan**

The datasets generated and/or analysed during the current study are not expected to be made available because of their high commercial sensitivity and the negligible benefit to the public of publication of results of non-therapeutic clinical trials.

**IPD sharing plan summary**

Not expected to be made available